During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...

During a live event, Christine Bestvina, MD, discussed trials of KRAS inhibitors plus immunotherapy in patients with ...

An expert discusses that while CAR T-cell therapy has transformed the treatment landscape for primary refractory diffuse ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

A recent study reveals low rates of upper tract urothelial carcinoma in non-muscle-invasive bladder cancer, prompting a ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...

An expert discusses that this case of a 60-year-old man with primary refractory diffuse large B-cell lymphoma highlights the urgent need for a shift in therapeutic strategy following early relapse ...

In an interview with Targeted Oncology, Benjamin Schlechter, MD, Senior Physician in the Gastrointestinal Cancer Center at the Dana-Farber Cancer Institute, discusses the unmet needs for patients with ...

Bonilla, MD, MSEd, discusses the significant advancements and ongoing efforts in integrating artificial intelligence into oncology.

During a live event, Mark Yarchoan, MD, and participants discussed their impressions of the CheckMate-9DW trial data in ...

Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete ...

ASCO 2025 showcased breakthroughs in sarcoma treatment, emphasizing precision medicine, immunotherapy, and promising new ...